Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib + Obinutuzumab + Lenalidomide vs Obinutuzumab + Chemotherapy in Treatment-Naive Follicular Lymphoma
NCT07719855Phase 3Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2026
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in follicular lymphoma (FL), sponsored by Ruijin Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07719855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07719855.